OncoMatch

OncoMatch/Clinical Trials/NCT06547528

A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL

Is NCT06547528 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies ONO-4685 for relapsed or refractory t cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.

Phase 1RecruitingOno Pharmaceutical Co. LtdNCT06547528Data as of Jun 2026Location: Japan

Treatment: ONO-4685A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

ONO-4685

Cancer type

Chronic Lymphocytic Leukemia

Non-Hodgkin Lymphoma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06547528 currently recruiting?

Yes, this trial is currently recruiting patients.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify